文献速递膀胱癌与上尿路尿路上皮癌

序贯膀胱内灌注戊柔比星和多西他赛用于非肌层浸润性膀胱癌的挽救治疗

Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non-Muscle-Invasive Bladder Cancer.
PubMed 文献 · J Urol · 2022-07-05

本文回顾性分析了2013年4月至2021年6月间75例接受序贯膀胱内灌注戊柔比星和多西他赛治疗的复发性非肌层浸润性膀胱癌患者,中位随访21个月。低级别组2年无复发生发生率为73%,高级别组2年高级别无复发生发生率为38%。作者认为该方案是复发性非肌层浸润性膀胱癌的有效挽救治疗,需进一步前瞻性评估。

要点

  • 低级别患者2年无复发生发生率为73%,高级别患者2年高级别无复发生发生率为38%。
  • 42例(56%)患者合并原位癌,有无原位癌的无复发生发生无显著差异(P=0.63)。
  • 高级别患者2年总生存率87%、肿瘤特异性生存率96%、免膀胱切除生存率84%。

核心结论

  • 在经大量预先治疗的人群中,作者认为戊柔比星和多西他赛是复发性非肌层浸润性膀胱癌的有效挽救治疗,需进一步前瞻性评估。

研究设计与样本

  • 回顾性研究,纳入2013年4月至2021年6月间接受戊柔比星和多西他赛治疗的复发性非肌层浸润性膀胱癌患者75例,中位随访21个月(IQR:13-37)。

主要发现

  • 低级别疾病患者12例,2年无复发生发生率为73%。
  • 复发性高级别疾病患者63例,2年高级别无复发生发生率为38%。
  • 42例(56%)患者存在原位癌,有无原位癌的无复发生发生相似(P=0.63)。
  • 2例死于转移性膀胱癌,10例接受膀胱切除术。
  • 高级别疾病患者2年总生存率87%、肿瘤特异性生存率96%、免膀胱切除生存率84%。

关键数值与推荐

  • 患者接受每周序贯膀胱内灌注800 mg戊柔比星和37.5 mg多西他赛,共6周。
  • 首次随访无疾病者开始每月维持治疗,持续2年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intravesical gemcitabine-docetaxel has emerged as an efficacious and well-tolerated salvage therapy for non-muscle-invasive bladder cancer. However, further rescue therapies are needed for subsequent recurrences or intolerance, particularly when cystectomy is refused or precluded. Valrubicin is a U.S. Food and Drug Administration-approved agent for bacillus Calmette-Guérin unresponsive disease, yet as monotherapy has demonstrated poor efficacy. We report our experience with sequential intravesical valrubicin and docetaxel as a rescue therapy for non-muscle-invasive bladder cancer. MATERIALS AND METHODS: We retrospectively identified all patients with recurrent non-muscle-invasive bladder cancer treated with valrubicin and docetaxel between April 2013 and June 2021. Patients received weekly sequential intravesical instillations of 800 mg valrubicin and 37.5 mg docetaxel for 6 weeks. If disease-free at first follow-up, monthly maintenance of 2 years was initiated. The primary outcome was recurrence-free survival, assessed using the Kaplan-Meier method. RESULTS: The analysis included 75 patients with median follow-up of 21 months (IQR: 13-37). Twelve patients with low-grade disease had a 73% recurrence-free survival at 2 years. Sixty-three patients with recurrent high-grade disease had a 38% 2-year high-grade recurrence-free survival. Forty-two (56%) patients had carcinoma in situ present; recurrence-free survival was similar for those with and without carcinoma in situ (P = .63). Two patients died of metastatic bladder cancer while 10 underwent cystectomy. Among patients with high-grade disease, overall, cancer-specific, and cystectomy-free survivals were 87%, 96%, and 84% at 2 years, respectively. Adverse events included bladder spasms (n = 18), urinary frequency (n = 10), and dysuria (n = 8). Two patients could not tolerate valrubicin and docetaxel induction. CONCLUSIONS: In a heavily pretreated population, our results suggest valrubicin and docetaxel is an effective rescue treatment for patients with recurrent non-muscle-invasive bladder cancer. Further prospective evaluation is needed.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. McElree IM, Packiam VT, Steinberg RL, et al. Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non-Muscle-Invasive Bladder Cancer. J Urol. 2022. PMID: 35830552. doi:10.1097/JU.0000000000002848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。